Search Results
Found 2 results
510(k) Data Aggregation
(28 days)
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs and Fentanyl
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs and Fentanyl) is a disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. In addition, these gloves were tested for use with Chemotherapy drugs and Fentanyl in accordance with ASTM D6978-05 (2019) Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs and Fentanyl) is a Class I patient examination gloves bearing the product codes LZA, LZC, OPJ, QDO (21 CFR 880.6250). They meet all the current specifications listed under the ASTM D6319-19. Standard Specification for Nitrile Examination Gloves for Medical Application and also complies with requirements for Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs as per ASTM D6978-05 (2019). They are made from Nitrile (NBR). These gloves are blue in color and are powder free. The product is non-sterile, fingertip textured, ambidextrous with beaded cuff and single use only.
This document is a 510(k) Premarket Notification from the FDA for medical gloves, specifically "Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs and Fentanyl)". It details the device's technical characteristics, indications for use, and a comparison to a predicate device, along with non-clinical testing results to demonstrate substantial equivalence.
Here's an analysis based on your request, focusing on the acceptance criteria and the study that proves the device meets them:
1. Table of Acceptance Criteria and the Reported Device Performance
The acceptance criteria and performance data are primarily described in the "NON-CLINICAL TESTING SUMMARY PERFORMANCE DATA" and "BIOCOMPATIBILITY DATA" sections (pages 9-12).
Test Method (Standard) | Purpose | Acceptance Criteria | Reported Device Performance |
---|---|---|---|
ASTM D6319-19 (Dimensions - Length) | To determine the length of the gloves | Medium: 230 mm min; Large: 230 mm min; X-Large: 230 mm min; XX-Large: 230 mm min | Medium: 235 mm; Large: 237 mm; X-Large: 250 mm; XX-Large: 238 mm |
ASTM D6319-19 (Dimensions - Width) | To determine the width of the gloves | Medium: 95+/-10 mm; Large: 110+/-10 mm; X-Large: 120+/-10 mm; XX-Large: 130+/-10 mm | Medium: 95; Large: 113; X-Large: 121; XX-Large: 129 |
ASTM D6319-19 (Thickness) | To determine the thickness of the gloves | Palm: 0.05 mm min for all sizes; Finger: 0.05 mm min for all sizes | Medium: Palm 0.077 mm, Finger 0.111 mm; Large: Palm 0.106 mm, Finger 0.109 mm; X-Large: Palm 0.089 mm, Finger 0.115 mm; XX-Large: Palm 0.113 mm, Finger 0.107 mm |
ASTM D6319-19 (Physical Properties - Tensile Strength) | To determine the physical properties - Tensile strength | Before Ageing: 14MPa min for all sizes; After Ageing: 14MPa min for all sizes | Medium: Before Ageing 34.0 MPa, After Ageing 37.3 MPa (Only Medium size result provided, table formatting appears to omit others) |
ASTM D6319-19 (Physical Properties - Ultimate Elongation) | To determine the physical properties - Ultimate Elongation | Before Ageing: 500% min for all sizes; After Ageing: 400% min for all sizes | Medium: Before Ageing 542%, After Ageing 503% (Only Medium size result provided, table formatting appears to omit others) |
ASTM D5151-19 | To determine the holes in the gloves | AQL 2.5 | Gloves Pass AQL 2.5 |
ASTM D6124-06 (Reapproved 2017) | To determine the residual powder in the gloves | ≤ 2 mg/glove | Medium: 0.3516 mg/glove (Only Medium size result provided, table formatting appears to omit others) |
ASTM D6978-05 (Reapproved 2019) (Chemotherapy Drugs) | To determine the breakthrough detection time of chemotherapy drugs | Generally ">240 Minutes" for most listed drugs (e.g., Bleomycin Sulfate 15mg/ml >240 Minutes, Busulfan 6 mg/ml >240 Minutes, Carboplatin 10 mg/ml >240 Minutes, etc.) With specific lower times for Carmustine (33.8 mins) and Thiotepa (128.1 mins), and a "Warning: Not for Use with: Carmustine, Thiotepa" based on these low permeation times. | Results matched acceptance criteria: ">240 Minutes" for the majority of listed drugs, and the specified lower times for Carmustine (33.8 mins) and Thiotepa (128.1 mins) were reported. |
ASTM D6978-05 (Reapproved 2019) (Opioid Drugs) | To determine the breakthrough detection time of Opioid drugs | Fentanyl Citrate Injection (100mcg/2mL) >240 Minutes | Fentanyl Citrate Injection (100mcg/2mL) >240 Minutes |
ISO 10993-23 First edition 2021-01 (Irritation) | To evaluate the local dermal irritation of a test article extract | Under the condition of study not an irritant | Under the conditions of the study, the test article met the requirements of the test. |
ISO 10993-10 Fourth edition 2021-11 (Skin Sensitization) | To evaluate the test item for skin sensitization | Under the conditions of the study, not a sensitizer | Under the conditions of the study, the test article was not considered a sensitizer. |
ISO 10993-5 Third edition 2009-06-01 (In Vitro Cytotoxicity) | To determine the potential of a test article to cause cytotoxicity | Under the conditions of the study, non-cytotoxic | The undiluted test article extract and 50% test article extract dilution did not meet the requirements of the test and the 25%, 12.5%, 6.25%, and 3.13% test article extract dilutions met the requirements of the test. Cytotoxicity concern was addressed by acute systemic toxicity testing. (Note: This result indicates that higher concentrations were not non-cytotoxic, but the justification points to systemic toxicity testing to mitigate this concern.) |
ISO 10993-11 Third edition 2017-09 (Acute Systemic Toxicity) | To evaluate the acute systemic toxicity of a test article extract | Under the conditions of study, the device extracts do not pose a systemic toxicity concern | Under the conditions of study, there was no mortality or evidence of systemic toxicity. |
2. Sample Size Used for the Test Set and the Data Provenance
The document does not explicitly state the exact sample sizes used for each specific test (e.g., number of gloves tested for permeation, dimensions, etc.) beyond what's implied by the AQL 2.5 for freedom from holes (which dictates the sampling plan based on lot size, but the lot size isn't provided).
- Data Provenance: The studies were non-clinical bench tests and biocompatibility tests performed to established ASTM and ISO standards. The location where these tests were conducted is not specified in this FDA letter, but typically these are performed in certified laboratories. The data is prospective, in the sense that the tests were conducted specifically to demonstrate the performance of the device for this submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
This document describes a 510(k) submission for an examination glove, which is a Class I medical device. The "ground truth" for these tests are established by widely accepted international and national standards (ASTM and ISO). These standards themselves are developed by committees of experts in relevant fields (materials science, chemistry, toxicology, medical device manufacturing, etc.), and the laboratories performing the tests follow strict protocols defined by these standards.
The document does not mention the use of individual human experts (like radiologists for imaging studies) to establish "ground truth" for the performance or safety of the glove itself in the way that would apply to, for example, an AI diagnostic aid. The "ground truth" for the glove's performance is derived directly from the application of the specified physical, chemical, and biological test methods.
4. Adjudication Method for the Test Set
Not applicable in the context of this device and testing. Adjudication methods (like 2+1, 3+1 consensus) are relevant for subjective expert review processes, such as interpreting medical images or clinical outcomes. For the physical and chemical property tests of a glove, the results are quantitative measurements or pass/fail criteria against a defined standard, not subject to human interpretation discrepancies requiring adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done
No. An MRMC study is relevant for AI-powered diagnostic devices where human readers (e.g., radiologists) perform tasks with and without AI assistance to measure the AI's impact on human performance. This document pertains to a physical medical device (examination glove), not an AI diagnostic system.
6. If a Standalone (i.e. algorithm only without human-in-the loop performance) was done
Not applicable. This device is a glove, not an algorithm. The performance tests are "standalone" in the sense that they measure the intrinsic properties of the glove itself.
7. The Type of Ground Truth Used
The ground truth for this device is based on defined physical, chemical, and biological performance standards and test methodologies (e.g., ASTM D6319-19 for glove properties, ASTM D6978-05 for chemical permeation resistance, ISO 10993 series for biocompatibility). These standards specify the methods for measuring parameters like tensile strength, freedom from holes, chemical breakthrough time, and biological responses (irritation, sensitization, cytotoxicity, systemic toxicity).
8. The Sample Size for the Training Set
Not applicable. This document is about a physical medical device (glove), not a machine learning or AI model. Therefore, there is no "training set."
9. How the Ground Truth for the Training Set was Established
Not applicable, as there is no training set for this type of medical device submission.
Ask a specific question about this device
(73 days)
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs)
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs) is a disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 (2019) Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.
The following chemotherapy drugs and concentration had NO breakthrough detected up to 240 minutes:
Bleomycin Sulfate (15.0 mg/ml)
Busulfan (6.0 mg/ml)
Carboplatin (10.0 mg/ml)
Cisplatin (1.0 mg/ml)
Cyclophosphamide (20.0 mg/ml)
Cytarabine (100.0 mg/ml)
Dacarbazine (10.0 mg/ml)
Daunorubicin HCl (5.0 mg/ml)
Docetaxel (10.0 mg/ml)
Doxorubicin HCl (2.0 mg/ml)
Epirubicin HCl (2.0 mg/ml)
Etoposide (20.0 mg/ml)
Fludarabine (25.0 mg/ml)
Fluorouracil (50.0 mg/ml)
Gemcitabine (38.0 mg/ml)
Idarubicin HCl (1.0 mg/ml)
Ifosfamide (50.0 mg/ml)
Irinotecan (20.0 mg/ml)
Mechlorethamine HCl (1.0 mg/ml)
Melphalan (5.0 mg/ml)
Methotrexate (25.0 mg/ml)
Mitomycin C (0.5 mg/ml)
Mitoxantrone HCl (2.0 mg/ml)
Paclitaxel (6.0 mg/ml)
Rituximab (10.0 mg/ml)
Trisenox (1.0 mg/ml)
Vincristine Sulfate (1.0 mg/ml)
The following chemotherapy drugs have low permeation times: Carmustine (3.3 mg/ml) : 33.8 minutes Thiotepa (10.0 mg/ml) : 128.1 minutes
Warning: Not for Use with: Carmustine, Thiotepa
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs) is a Class I, patient examination gloves bearing the product codes LZA, LZC, OPJ (21CFR880.6250). They meet all the current specifications listed under the ASTM D6319-19, Standard Specification for Nitrile Examination Gloves for Medical Application and also complies with requirements for Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs as per ASTM D6978-05 (2019). They are made from Nitrile (NBR). These gloves are blue in color and are powder free. The product is non-sterile, fingertip textured, ambidextrous with beaded cuff and single use only.
Nephron Nitrile Powder-Free Nitrile Examination Gloves (Tested For Use With Chemotherapy Drugs) with sizes Medium, Large, X-Large and XX-Large are included in the submission.
The provided text describes the acceptance criteria and performance of the Nephron Nitrile Powder-Free Nitrile Examination Gloves.
Here's the requested information:
1. A table of acceptance criteria and the reported device performance
Test Method (Standard) | Purpose | Acceptance Criteria | Reported Device Performance |
---|---|---|---|
ASTM D6319-19 (Dimensions - Length) | To determine the length of the gloves | Medium: 230 mm min | |
Large: 230 mm min | |||
X-Large: 230 mm min | |||
XX-Large: 230 mm min | Medium: 235 mm | ||
Large: 237 mm | |||
X-Large: 250 mm | |||
XX-Large: 238 mm | |||
ASTM D6319-19 (Dimensions - Width) | To determine the width of the gloves | Medium: 95+/-10 mm | |
Large: 110+/-10 mm | |||
X-Large: 120+/-10 mm | |||
XX-Large: 130+/-10 mm | Medium: 95 mm | ||
Large: 113 mm | |||
X-Large: 121 mm | |||
XX-Large: 129 mm | |||
ASTM D6319-19 (Thickness) | To determine the thickness of the gloves | Palm: 0.05 mm min for all sizes | |
Finger: 0.05 mm min for all sizes | Size Palm (Avg value) Finger (Avg value) | ||
Medium 0.077 mm 0.111 mm | |||
Large 0.106 mm 0.109 mm | |||
X-Large 0.089 mm 0.115 mm | |||
XX-Large 0.113 mm 0.107 mm | |||
ASTM D6319-19 (Physical Properties - Tensile Strength) | To determine the physical properties - Tensile strength | Before Ageing Tensile Strength: 14MPa min for all sizes | |
After Ageing Tensile Strength: 14MPa min for all sizes | Size Before ageing After ageing | ||
Medium 34.0 MPa 37.3 MPa | |||
ASTM D6319-19 (Physical Properties - Ultimate Elongation) | To determine the physical properties - Ultimate Elongation | Before Ageing Ultimate Elongation: 500% min for all sizes | |
After Ageing Ultimate Elongation: 400% min for all sizes | Size Before ageing After ageing | ||
Medium 542% 503% | |||
ASTM D5151-19 (Freedom from holes) | To determine the holes in the gloves | AQL 2.5 | Gloves Passes AQL 2.5 |
ASTM D6124-06 (Residual Powder) | To determine the residual powder in the gloves | ≤ 2 mg/glove | Medium: 0.3516 mg/glove |
ASTM D6978-05 (Chemotherapy Drugs Permeation) | To determine the breakthrough detection time of chemotherapy drugs | For listed drugs (e.g., Bleomycin Sulfate, Busulfan, Carboplatin, Cisplatin, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin HCl, Docetaxel, Doxorubicin HCl, Epirubicin HCl, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin HCl, Ifosfamide, Irinotecan, Mechlorethamine HCl, Melphalan, Methotrexate, Mitomycin C, Mitoxantrone HCl, Paclitaxel, Rituximab, Trisenox, Vincristine Sulfate): >240 Minutes. | |
Carmustine (3.3 mg/ml): Not specified as a pass/fail criterion, but a low permeation time is noted. | |||
Thiotepa (10.0 mg/ml): Not specified as a pass/fail criterion, but a low permeation time is noted. | For all 28 listed chemotherapy drugs, the breakthrough detection time was >240 Minutes. | ||
Carmustine (3.3 mg/ml) : 33.8 minutes | |||
Thiotepa (10.0 mg/ml) : 128.1 minutes | |||
ISO 10993-23 (Primary Skin Irritation) | To evaluate the local dermal irritation in rabbits | Under the condition of study not an irritant | Under the conditions of the study, the test article met the requirements of the test. |
ISO 10993-10 (Dermal Sensitization) | To evaluate the skin sensitization in Guinea pigs | Under the conditions of the study, not a sensitizer | Under the conditions of the study, the test article was not considered a sensitizer. |
ISO 10993-5 (In Vitro Cytotoxicity) | To determine the potential to cause cytotoxicity | Under the conditions of the study, non-cytotoxic | The undiluted test article extract and 50% test article extract dilution did not meet the requirements of the test and the 25%, 12.5%, 6.25%, and 3.13% test article extract dilutions met the requirements of the test. The cytotoxic concern was addressed via acute systemic toxicity testing. (This result indicates some cytotoxicity at higher concentrations but was mitigated by systemic toxicity testing). |
ISO 10993-11 (Acute Systemic Toxicity) | To evaluate the acute systemic toxicity in mice | Under the conditions of study, the device extracts do not pose a systemic toxicity concern | Under the conditions of study, there was no mortality or evidence of systemic toxicity. |
2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
The document does not explicitly state the sample sizes for each test in the level of detail (e.g., number of gloves tested for each specific property or chemotherapy drug). It only refers to compliance with the standards (e.g., AQL 2.5 for freedom from holes).
The data provenance (country of origin, retrospective/prospective) is not mentioned. These are bench tests, not human trials or medical imaging data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)
This information is not applicable. The document describes bench testing of physical and chemical properties of gloves, not expert interpretation of medical images or clinical data.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This information is not applicable. The tests are laboratory-based and follow standardized testing protocols, which do not typically involve adjudication methods like those used for expert review of clinical cases.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not applicable. The document describes the testing of medical examination gloves, which are physical products, not AI systems or medical imaging devices. Therefore, MRMC studies and AI assistance are irrelevant.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This information is not applicable. The document describes the testing of medical examination gloves, which are physical products, not algorithms.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The "ground truth" for these tests is defined by the technical specifications and performance requirements outlined in the referenced ASTM and ISO standards. For example:
- Physical properties (length, width, thickness, tensile strength, elongation) are measured objectively against defined numerical limits.
- Freedom from holes is assessed against an Acceptable Quality Limit (AQL), a statistical measure.
- Resistance to chemotherapy drugs is measured by detecting breakthrough time using specific analytical methods defined in ASTM D6978.
- Biocompatibility tests (irritation, sensitization, cytotoxicity, systemic toxicity) are assessed by observing biological responses in animal models or in vitro systems against established criteria for non-irritancy, non-sensitization, and non-toxicity according to ISO standards.
Essentially, the "ground truth" reflects compliance with regulatory and industry standards for glove performance and safety.
8. The sample size for the training set
This information is not applicable, as this is not a machine learning model.
9. How the ground truth for the training set was established
This information is not applicable, as this is not a machine learning model.
Ask a specific question about this device
Page 1 of 1